AgomAb Therapeutics (NASDAQ:AGMB) CFO Pierre Thadee Victor Kemula Purchases 10,000 Shares of Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) CFO Pierre Thadee Victor Kemula bought 10,000 shares of the company’s stock in a transaction on Tuesday, October 6th. The stock was bought at an average cost of $8.59 per share, with a total value of $85,900.00. Following the completion of the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at approximately $85,900. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

AgomAb Therapeutics Trading Up 1.7%

Shares of AGMB stock opened at $8.84 on Wednesday. AgomAb Therapeutics NV has a 1 year low of $7.97 and a 1 year high of $17.82. The firm’s 50 day moving average is $12.82 and its 200-day moving average is $12.00.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Equities research analysts anticipate that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Piper Sandler started coverage on AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price on the stock. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They issued an “overweight” rating on the stock. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Finally, Wall Street Zen downgraded shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.